TENOFOVIR ALAFENAMIDE , Placebo capules, hard clinical trials

TARGET-EBV in MS: A prospective randomized controlled parallel group phase 2b double blinded study to investigate if targeting Epstein Barr Virus with Tenofovir Alafenamide Fumarate compared to placebo as add-on treatment to anti-CD20 therapy reduces neuronal damage in multiple sclerosis

This study looks into whether a drug called Tenofovir Alafenamide, given alongside a standard MS treatment, can help reduce nerve damage in people with multiple sclerosis by targeting the Epstein-Barr virus. It compares the drug to a dummy pill.